Skip to content
2000
Volume 33, Issue 3
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Introduction

, a significant fungal pathogen, poses a threat to human health, especially in immunocompromised individuals. Addressing the need for novel antifungal strategies, this study employs virtual screening to identify potential inhibitors of Fructosamine oxidase, also known as Amadoriase II, a crucial enzyme in (PDB ID: 3DJE).

Methods

Virtual screening of 81,197 triazole derivatives was subjected to computational analysis, aiming to pinpoint molecules with high binding affinity to the active site of Fructosamine oxidase. Subsequently, an in-depth ADMET analysis assessed the pharmacokinetic properties of lead compounds, ensuring their viability for further development. Molecular dynamics simulations were performed to evaluate the stability of top-ranked compounds over time.

Results

The results unveil a subset of triazole derivatives displaying promising interactions, suggesting their potential as inhibitors for further investigation.

Conclusion

This approach contributes to the development of targeted antifungal agents, offering a rational starting point for experimental validation and drug development against infections.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0109298673321782240829082610
2024-09-12
2026-02-23
Loading full text...

Full text loading...

References

  1. ArastehfarA. CarvalhoA. HoubrakenJ. LombardiL. Garcia-RubioR. JenksJ.D. Rivero-MenendezO. AljohaniR. JacobsenI.D. BermanJ. OsherovN. HedayatiM.T. IlkitM. Armstrong-JamesD. GabaldónT. MeletiadisJ. KostrzewaM. PanW. Lass-FlörlC. PerlinD.S. HoeniglM. Aspergillus fumigatus and aspergillosis: From basics to clinics.Stud. Mycol.2021100110011510011510.1016/j.simyco.2021.10011534035866
    [Google Scholar]
  2. JanbonG. QuintinJ. LanternierF. d’EnfertC. Studying fungal pathogens of humans and fungal infections: fungal diversity and diversity of approaches.Genes Immun.201920540341410.1038/s41435‑019‑0071‑231019254
    [Google Scholar]
  3. BandresM.V. ModiP. SharmaS. Aspergillus fumigatus (Archived).StatPearlsTreasure Island (FL): StatPearls Publishing2024
    [Google Scholar]
  4. PerfectJ.R. The antifungal pipeline: a reality check.Nat. Rev. Drug Discov.201716960361610.1038/nrd.2017.4628496146
    [Google Scholar]
  5. RoemerT. KrysanD.J. Antifungal drug development: challenges, unmet clinical needs, and new approaches.Cold Spring Harb. Perspect. Med.201445a019703a01970310.1101/cshperspect.a01970324789878
    [Google Scholar]
  6. Fernández de UllivarriM. ArbuluS. Garcia-GutierrezE. CotterP.D. Antifungal peptides as therapeutic agents.Front. Cell. Infect. Microbiol.20201010510.3389/fcimb.2020.0010532257965
    [Google Scholar]
  7. HoušťJ. SpížekJ. HavlíčekV. Antifungal drugs.Metabolites202010310610.3390/metabo1003010632178468
    [Google Scholar]
  8. RauseoA.M. Coler-ReillyA. LarsonL. SpecA. Hope on the horizon: novel fungal treatments in development.Open Forum Infect. Dis.202072ofaa01610.1093/ofid/ofaa01632099843
    [Google Scholar]
  9. ChoudharyM. KumarV. NaikB. VermaA. SarisP.E.J. KumarV. GuptaS. Antifungal metabolites, their novel sources, and targets to combat drug resistance.Front. Microbiol.202213106160310.3389/fmicb.2022.106160336532457
    [Google Scholar]
  10. PianaltoK. AlspaughJ. New horizons in antifungal therapy.J. Fungi (Basel)2016242610.3390/jof204002629376943
    [Google Scholar]
  11. CollardF. ZhangJ. NemetI. QanungoK.R. MonnierV.M. YeeV.C. Crystal structure of the deglycating enzyme fructosamine oxidase (amadoriase II).J. Biol. Chem.200828340270072701610.1074/jbc.M80488520018667417
    [Google Scholar]
  12. ShimasakiT. YoshidaH. KamitoriS. SodeK. X-ray structures of fructosyl peptide oxidases revealing residues responsible for gating oxygen access in the oxidative half reaction.Sci. Rep.201771279010.1038/s41598‑017‑02657‑528584265
    [Google Scholar]
  13. ZhengJ. GuanH. XuL. YangR. LinZ. Engineered amadoriase II exhibiting expanded substrate range.Appl. Microbiol. Biotechnol.201086260761310.1007/s00253‑009‑2319‑719888573
    [Google Scholar]
  14. NilssonR.H. AnslanS. BahramM. WurzbacherC. BaldrianP. TedersooL. Mycobiome diversity: high-throughput sequencing and identification of fungi.Nat. Rev. Microbiol.20191729510910.1038/s41579‑018‑0116‑y30442909
    [Google Scholar]
  15. ZhangM. Analysis of LOXL1 expression in gastric cancer and mining of traditional Chinese medicine based on bioinformatics.Cancer Cell Res.2024114192693210.54762/CCR2024.933‑942
    [Google Scholar]
  16. YamariI. MouhibA. Es-SounniB. NejjariR. MazoirN. BakhouchM. MouzdahirA. BenharrefA. El KoualiM. ChtitaS. Oxidative functionalization of triterpenes isolated from Euphorbia resinifera latex: Semisynthesis, ADME-Tox, molecular docking, and molecular dynamics simulations.Chemical Physics Impact2023710037210.1016/j.chphi.2023.100372
    [Google Scholar]
  17. AbchirO. DaouiO. BelaidiS. OuassafM. QaisF.A. ElKhattabiS. BelaaouadS. ChtitaS. Design of novel benzimidazole derivatives as potential α-amylase inhibitors using QSAR, pharmacokinetics, molecular docking, and molecular dynamics simulation studies.J. Mol. Model.202228410610.1007/s00894‑022‑05097‑935352175
    [Google Scholar]
  18. YamariI. AbchirO. MaliS.N. ErrouguiA. TalbiM. KoualiM.E. ChtitaS. The anti-SARS-CoV-2 activity of novel 9, 10-dihydrophenanthrene derivatives: an insight into molecular docking, ADMET analysis, and molecular dynamics simulation.Sci. Am.202321e0175410.1016/j.sciaf.2023.e0175437332393
    [Google Scholar]
  19. NourH. HashmiM.A. BelaidiS. ErrouguiA. El KoualiM. TalbiM. ChtitaS. Design of acetylcholinesterase inhibitors as promising anti-alzheimer’s agents based on QSAR, molecular docking, and molecular dynamics studies of liquiritigenin derivatives.ChemistrySelect2023832e20230146610.1002/slct.202301466
    [Google Scholar]
  20. KhedraouiM. NourH. YamariI. AbchirO. ErrouguiA. ChtitaS. Design of a new potent Alzheimer’s disease inhibitor based on QSAR, molecular docking and molecular dynamics investigations.Chemical Physics Impact2023710036110.1016/j.chphi.2023.100361
    [Google Scholar]
  21. AbchirO. YamariI. NourH. DaouiO. ElkhattabiS. ErrouguiA. ChtitaS. Structure-based virtual screening, ADMET analysis, and molecular dynamics simulation of moroccan natural compounds as candidates α-amylase inhibitors.ChemistrySelect2023826e20230109210.1002/slct.202301092
    [Google Scholar]
  22. SerafiniM. PiraliT. TronG.C. Chapter Three - Click 1,2,3-triazoles in drug discovery and development: From the flask to the clinic?Advances in Heterocyclic ChemistryAcademic Press Inc.202113410114810.1016/bs.aihch.2020.10.001
    [Google Scholar]
  23. GaoF. WangT. XiaoJ. HuangG. Antibacterial activity study of 1,2,4-triazole derivatives.Eur. J. Med. Chem.201917327428110.1016/j.ejmech.2019.04.04331009913
    [Google Scholar]
  24. MatinM.M. MatinP. RahmanM.R. Ben HaddaT. AlmalkiF.A. MahmudS. GhoneimM.M. AlruwailyM. AlshehriS. Triazoles and their derivatives: chemistry, synthesis, and therapeutic applications.Front. Mol. Biosci.2022986428610.3389/fmolb.2022.86428635547394
    [Google Scholar]
  25. StaśkiewiczA. LedwońP. RoveroP. PapiniA.M. LatajkaR. Triazole-modified peptidomimetics: An opportunity for drug discovery and development.Front Chem.2021967470510.3389/fchem.2021.67470534095086
    [Google Scholar]
  26. TianG. SongQ. LiuZ. GuoJ. CaoS. LongS. Recent advances in 1,2,3- and 1,2,4-triazole hybrids as antimicrobials and their SAR: A critical review.Eur. J. Med. Chem.202325911560310.1016/j.ejmech.2023.11560337478558
    [Google Scholar]
  27. Schrödinger, System, Maestro-Desmond Interoperability Tools, Software.2021Available from: https://www.schrodinger.com/platform/products/desmond/
  28. FriesnerR.A. BanksJ.L. MurphyR.B. HalgrenT.A. KlicicJ.J. MainzD.T. RepaskyM.P. KnollE.H. ShelleyM. PerryJ.K. ShawD.E. FrancisP. ShenkinP.S. Glide: a new approach for rapid, accurate docking and scoring. 1. Method and assessment of docking accuracy.J. Med. Chem.20044771739174910.1021/jm030643015027865
    [Google Scholar]
  29. Pubchem. Available from: https://pubchem.ncbi.nlm.nih.gov/
  30. Schrödinger Release 2024-1: LigPrep, Schrödinger, LLC, New York, NY.Available from: https://newsite.schrodinger.com/platform/products/ligprep/
  31. RoosK. WuC. DammW. ReboulM. StevensonJ.M. LuC. DahlgrenM.K. MondalS. ChenW. WangL. AbelR. FriesnerR.A. HarderE.D. OPLS3e: extending force field coverage for drug-like small molecules.J. Chem. Theory Comput.20191531863187410.1021/acs.jctc.8b0102630768902
    [Google Scholar]
  32. ShelleyJ.C. CholletiA. FryeL.L. GreenwoodJ.R. TimlinM.R. UchimayaM. Epik: a software program for pK a prediction and protonation state generation for drug- like molecules.J. Comput. Aided Mol. Des.2007211268169110.1007/s10822‑007‑9133‑z17899391
    [Google Scholar]
  33. Procheck.Available from: https://saves.mbi.ucla.edu/
  34. LaskowskiR.A. MacArthurM.W. MossD.S. ThorntonJ.M. PROCHECK: a program to check the stereochemical quality of protein structures.J. Appl. Cryst.199326228329110.1107/S0021889892009944
    [Google Scholar]
  35. LaskowskiR. RullmannJ.A.C. MacArthurM. KapteinR. ThorntonJ. AQUA and PROCHECK-NMR: Programs for checking the quality of protein structures solved by NMR.J. Biomol. NMR19968447748610.1007/BF002281489008363
    [Google Scholar]
  36. BermanH.M. WestbrookJ. FengZ. GillilandG. BhatT.N. WeissigH. ShindyalovI.N. BourneP.E. The protein data bank.Nucleic Acids Res.200028123524210.1093/nar/28.1.23510592235
    [Google Scholar]
  37. Schrödinger Release 2018-4, Protein Preparation Wizard EpikSchrödinger, LLC: New York, NY2016
    [Google Scholar]
  38. TripathiN.M. BandyopadhyayA. High throughput virtual screening (HTVS) of peptide library: Technological advancement in ligand discovery.Eur. J. Med. Chem.202224311476610.1016/j.ejmech.2022.11476636122548
    [Google Scholar]
  39. DuJ. SunH. XiL. LiJ. YangY. LiuH. YaoX. Molecular modeling study of checkpoint kinase 1 inhibitors by multiple docking strategies and prime/MM–GBSA calculation.J. Comput. Chem.201132132800280910.1002/jcc.2185921717478
    [Google Scholar]
  40. GenhedenS. RydeU. The MM/PBSA and MM/GBSA methods to estimate ligand-binding affinities.Expert Opin. Drug Discov.201510544946110.1517/17460441.2015.103293625835573
    [Google Scholar]
  41. PiresD.E.V. BlundellT.L. AscherD.B. pkCSM: Predicting small-molecule pharmacokinetic and toxicity properties using graph-based signatures.J. Med. Chem.20155894066407210.1021/acs.jmedchem.5b0010425860834
    [Google Scholar]
  42. MarkP. NilssonL. Structure and dynamics of the TIP3P, SPC, and SPC/E water models at 298 K.J. Phys. Chem. A2001105439954996010.1021/jp003020w
    [Google Scholar]
  43. KeQ. GongX. LiaoS. DuanC. LiL. Effects of thermostats/barostats on physical properties of liquids by molecular dynamics simulations.J. Mol. Liq.202236512011610.1016/j.molliq.2022.120116
    [Google Scholar]
  44. LipinskiC.A. LombardoF. DominyB.W. FeeneyP.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings.Adv. Drug Deliv. Rev.2001461-332610.1016/S0169‑409X(00)00129‑011259830
    [Google Scholar]
/content/journals/cmc/10.2174/0109298673321782240829082610
Loading
/content/journals/cmc/10.2174/0109298673321782240829082610
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test